PSD4 and breast cancer: Since in BC patients, we found a correlation between the severity of the clinico-pathological data and the gradual loss of expression of EFA6B messenger7, we propose that PSD4/EFA6B could act as a haplo-insufficient tumor-antagonist gene63,64.